PeptideLabs Logo
PeptideLabs
All profiles

Tesamorelin + Ipamorelin

Non-standardised blend · Blends & catalogue terms

Discussed online as a growth-hormone signalling combination. The blend is not approved and lacks robust safety data.

Not FDA/EMA approvedWADA
LibraryNo account · this device only

Also known as: TSM + IP · TSM + IPA

Use at a glance

Tesamorelin + Ipamorelin

Discussed online as a growth-hormone signalling combination. The blend is not approved and lacks robust safety data.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
5/5: 167 µg167 µgScale in the source: 10 U
How often?
once per day
What time of day?
evening
What period?
Week 1–2

A U figure only applies to the source's exact composition, concentration and device scale. Without all three, it cannot be transferred to another blend vial or pen.

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

How is it used?
Identify every ingredient and its amount first. The same blend name can refer to different products.
Does it need mixing?
Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.
View preparationCheck sources
Overview of all entries

  • Tesamorelin + Ipamorelin · Week 1–2

    Online report · not medically verified

    5/5: 167 µg + 167 µg · 10 U · once per day · evening

  • Tesamorelin + Ipamorelin · Week 3–4

    Online report · not medically verified

    5/5: 333 µg + 333 µg · 20 U · once per day · evening

  • Tesamorelin + Ipamorelin · Week 5–8

    Online report · not medically verified

    5/5: 500 µg + 500 µg · 30 U · once per day · evening

  • Tesamorelin + Ipamorelin · Week 9–16

    Online report · not medically verified

    5/5: 667 µg + 667 µg · 40 U · once per day · evening

  • Tesamorelin + Ipamorelin · pause

    Online report · not medically verified

    — · 4–8 weeks · not reliably established

A U figure only applies to the source's exact composition, concentration and device scale. Without all three, it cannot be transferred to another blend vial or pen.

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

More factsNon-standardised blend · Blends & catalogue terms
Classification
Non-standardised blend · Blends & catalogue terms
Research focus
Discussed online as a growth-hormone signalling combination. The blend is not approved and lacks robust safety data.
Evidence
Anecdotal
Status
Not FDA/EMA approved

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

Community arithmetic, not a recommendation: An exactly labelled 10/3 mg vial +3 ml would give roughly 333 µg tesamorelin +100 µg ipamorelin at 10 U; a 5/5 mg vial +3 ml would give roughly 167 +167 µg at 10 U.

Profile evidence level: anecdotal.

Timing

The reference mostly describes once daily in the evening. No validated human timing exists for the combination.

No individual recommendation.

Cycle/duration

8–16 weeks are mentioned online; no direct combination study confirms benefit or safety.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.

Ratio-specific blend calculator

For the selected explicitly stated composition, this calculates total and per-component amounts for a U-100 draw. The ratio remains fixed to the chosen example.

The calculation uses final volume, which is not automatically the amount of water added. Excipients can change the volume; a concentration specified by the manufacturer takes priority.

Assumed composition

10 mg Tesamorelin + 3 mg Ipamorelin

Pre-blended vial

Documented calculation points

What the selected U-100 amount contains mathematically

Tesamorelin: 333.3 µg · Ipamorelin: 100 µg

More calculation values

Total concentration

4.333 mg/ml

Volume

0.1 ml

Total amount in draw

433.3 µg

Calculated draws

30

Concentration per component

Tesamorelin: 3.333 mg/ml · Ipamorelin: 1 mg/ml

Calculation aid only, not dosage, reconstitution or use advice. Use only when identity, each component amount and the ratio are independently confirmed. U-100 means 100 units per ml; other syringe scales are not interchangeable.

Complete ratio and U-100 examplesEach row applies only to the stated composition and assumed final volume. A different ratio produces different component amounts.

10/3 mg · 3 ml

10 U

Tesamorelin: 333.3 µg · Ipamorelin: 100 µg

Assumed final solution volume
3 ml
Volume
0.1 ml
Total amount in draw
433.3 µg

10/3 mg · 3 ml

20 U

Tesamorelin: 666.7 µg · Ipamorelin: 200 µg

Assumed final solution volume
3 ml
Volume
0.2 ml
Total amount in draw
866.7 µg

10/3 mg · 3 ml

30 U

Tesamorelin: 1 mg · Ipamorelin: 300 µg

Assumed final solution volume
3 ml
Volume
0.3 ml
Total amount in draw
1.3 mg

5/5 mg · 3 ml

10 U

Tesamorelin: 166.7 µg · Ipamorelin: 166.7 µg

Assumed final solution volume
3 ml
Volume
0.1 ml
Total amount in draw
333.3 µg

5/5 mg · 3 ml

20 U

Tesamorelin: 333.3 µg · Ipamorelin: 333.3 µg

Assumed final solution volume
3 ml
Volume
0.2 ml
Total amount in draw
666.7 µg

5/5 mg · 3 ml

30 U

Tesamorelin: 500 µg · Ipamorelin: 500 µg

Assumed final solution volume
3 ml
Volume
0.3 ml
Total amount in draw
1 mg

5/5 mg · 3 ml

40 U

Tesamorelin: 666.7 µg · Ipamorelin: 666.7 µg

Assumed final solution volume
3 ml
Volume
0.4 ml
Total amount in draw
1.333 mg
All preparation informationProduct details and calculation examples from the available sources.

No blanket blend conversion. Only an exactly confirmed amount of each component and the actual total volume allow the pure arithmetic; the approved single-agent tesamorelin product does not validate the blend.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Non-standardised combination of two growth-hormone signalling compounds

Tesamorelin + Ipamorelin is classified as “Non-standardised combination of two growth-hormone signalling compounds”. Discussed online as a growth-hormone signalling combination. The blend is not approved and lacks robust safety data. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Growth hormone signalling blend

This studies how several substances that each stimulate growth hormone release are combined by vendors, similar to pressing several buttons at once for the same effect. Individual agents are usually studied, not the combined product.

02

GHRH analogue

This examines whether a growth hormone-releasing hormone analogue prompts the pituitary gland to release its own growth hormone, like a signal instructing the gland to release. Researchers measure growth hormone and IGF-1 levels in blood.

03

Ghrelin secretagogue

This checks how a substance stimulates growth hormone release through the ghrelin receptor, similar to how the body's own hunger hormone does. Measures include growth hormone peaks in blood and appetite changes.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Stack and blend discussion

Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Vendor marketing claims

Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.

Adverse effects and safety risks

  • Blends combine not only possible effects but also uncertainty, interactions, dosing errors and stability problems. An effect cannot be assigned reliably to one component.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • No use should be inferred without full qualitative and quantitative composition, batch testing and stability data; every comorbidity and medicine adds concern.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No validated monitoring exists for non-standardised blends. Individual lab values cannot make an unknown composition or interaction safe.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Anecdotal

The blend is not approved and lacks robust safety data.

Clinical evidence

Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.

This combination pairs an approved GHRH analogue with an unapproved secretagogue; the blend itself is not approved.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

This profile is marked as WADA-relevant. Check the current Prohibited List and the specific sport or route in the original; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile